Advances in Diagnosis and Management of Peyronie’s Diseases

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1034

Special Issue Editor


E-Mail Website
Guest Editor
Division of Urology, University Hospital of Marche, 71 Conca Street, 60126 Ancona, Italy
Interests: imaging; prostate cancer; renal cancer; andrology; new diagnostics technologies; robotic surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Peyronie’s disease (PD) is an acquired fibrotic degeneration affecting the tunica albuginea of the corpora cavernosa. The prevalence of this disease in men ranges from 0.4% to 7%.

PD is characterized by an idiopathic acute inflammatory stage with the formation of one or more plaques followed by a chronic phase where the plaques become stable across 12 to 14 months. The cause is unknown, but the prevailing theory is one of repeated micro-trauma to the corpora cavernosa during sexual intercourse.

However, not all men who suffer mild trauma to the penis acquire PD. For this reason, most researchers believe there must be genetic or environmental reasons as to why PD plaques form.

Dynamic ultrasound and/or MRI are generally used to study plaques and penile curvature, checking for calcium buildup and demonstrating the blood flow of the penis.

Management for PD during the active phase includes conservative therapy. The current literature does not support treatment based on predicting which patients with PD are more likely to progress in terms of clinical outcomes.

Surgery is reserved for men with more severe penile deformities and those in the chronic stage of the disease.

Precision medicine will allow us to design tailored therapy, according to the phase of the disease and the main clinical manifestations.

This Special Issue aims to shed light on the mechanisms underlying the onset and the progression of this ‘difficult’ disease, which may be useful for the development of new diagnostic or prognostic genetic factors and/or new therapeutic models. Original research articles and reviews are equally welcome and may include clinical and experimental research studies on different stages and disease models.

You may choose our Joint Special Issue in Diagnostics.

Dr. Lucio Dell'Atti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Peyronie’s disease
  • fibrotic degeneration
  • penis trauma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 221 KiB  
Article
Vacuum Erection Device Plus Once-Daily Tadalafil Improve Clinical Outcomes after Extracorporeal Shock Wave Therapy in Men Affected by Erectile Dysfunction Associated with Peyronie’s Disease
by Lucio Dell’Atti, Viktoria Slyusar, Piero Ronchi and Chiara Cambise
Life 2024, 14(9), 1162; https://doi.org/10.3390/life14091162 - 13 Sep 2024
Viewed by 875
Abstract
Background: The purpose of this study is to examine the combination of the mechanical effects of penile therapy with vacuum erection devices (VEDs) plus PDE5i, which improve clinical outcomes after extracorporeal shockwave therapy (ESWT) in men affected by erectile dysfunction (ED) associated with [...] Read more.
Background: The purpose of this study is to examine the combination of the mechanical effects of penile therapy with vacuum erection devices (VEDs) plus PDE5i, which improve clinical outcomes after extracorporeal shockwave therapy (ESWT) in men affected by erectile dysfunction (ED) associated with Peyronie’s disease (PD). Methods: A total of 153 medical records of patients affected by PD in stable stage with ED and treated with ESWT were divided into two groups. Group A (GA) included 72 men treated with ESWT, mechanical stretching with VEDs and PDE5ì (Tadalafil 5 mg), and Group B (GB) included 81 men who received only ESWT plus Tadalafil 5 mg with the same protocol of GA. The patients in both groups were assessed at baseline and follow-up for erectile function, painful erections, penile plaque size, and penile curvature. The results were evaluated at baseline and 3, 6, and 12 months after the treatments. Results: Three months after the treatment, GA patients had a reduction in penile curvature degree from a mean ± SD of 33.91 ± 8.34° at baseline to a mean ± SD of 19.46 ± 7.15° after 12 months, whereas pain in an erection or during intercourse was resolved completely in 88.9% of the patients. The mean ± SD IIEF-15 score of patients affected by severe/moderate ED further improved significantly in the GA group (p < 0.001) after 3, 6, and 12 months of treatment. There were no permanent adverse sequelae after treatments. Conclusions: The regular use of a VED plus Tadalafil in patients who had undergone ESWT significantly provided more benefit in patients with PD in terms of penile deformity, pain, and erectile function. Full article
(This article belongs to the Special Issue Advances in Diagnosis and Management of Peyronie’s Diseases)
Back to TopTop